§
Cui Bono
Bills Search Find My Rep Legislators Who Benefits Countries Methodology
Back to Legislators
Mr. Armstrong

Mr. Armstrong

0
Sponsored
5
Cosponsored
—
Votes

Policy Effects

Estimated effects on people, organizations, and industries in bills this legislator sponsored, cosponsored, or voted on. Includes bills they voted against.

These are assessments of legislative text, not measurements of realized outcomes or the legislator’s intent.

Patients and clinicians: supporting evidence

2 identified effects across 2 analyzed clauses in 1 bill.

Numbers count identified effects. One clause can affect several groups or contain several effects.

S3788-119

Reported

CLEAR LABELS Act

Mr. Armstrong’s recorded connection

Cosponsored this bill

  • Potential benefit to Patients and clinicians

    Lower risk

Summary unavailable

2. Require drug labels to include original manufacturer and supply chain information Section 503 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353) is amended by adding at the end the following — (i)Original Manufacturer and Supply Chain Information(1)In generalNo person shall introduce or deliver for introduction into interstate commerce any drug—(A)if it is an active pharmaceutical ing…

Section iddb83da3ec3534be98c94da7e3e04f5de Analyzed version: Reported in Senate (Jul 27, 2026)

View analysis Source text (opens in a new tab)↗ View full bill

  • Potential benefit to Patients and clinicians

    Lower risk

Adds or tightens a compliance mandate, definition change, delegation of rulemaking provision: 2. Require drug labeling to include original manufacturer and supply chain information Section 502(b) of the Federal Food,... In practical terms, health care providers and patients face compliance burden up (negative); Federal implementing agencies face compliance burden up (negative).

Section idd7b7c7b4d2e3473eb976eef8adf16551 Analyzed version: Introduced in Senate (Feb 5, 2026)

View analysis Source text (opens in a new tab)↗ View full bill

Clause analysis
What the effects and counts mean

Potential benefits are effects assessed as favorable to the named group. Potential burdens impose costs, restrictions, risks, or lost opportunities on that group.

Mixed effects contain countervailing effects on the same group. Unclear effects have an undetermined direction. A group can have separate benefits and burdens; these are counted separately.

Counts describe the number of identified effects, not their size or public value. Bill and clause counts are distinct within each view. Shared evidence may appear under several groups or policy areas, so their counts should not be added together.

Historical bill versions are included. Clauses analyzed in different versions count separately. A bill’s current status does not establish that every analyzed provision was enacted.

Only direct effects with high or medium confidence in the policy-area assignment are included. Bills are connected through sponsorship, cosponsorship, or Yea/Nay votes; a vote against a bill does not reverse its assessed effects. Vote dates filter recorded votes and vote-linked bills; sponsorship remains included.

Sponsored & Cosponsored Bills

All Roles Sponsor Cosponsor
All Industries Education Environment Federal Administration Finance General Public Government Healthcare Intellectual Property International Travelers Outdoor Recreation Professional Services State & Local Government Technology Tourism Travel Services Tribal Nations

Loading countries...

Explore affected groups in Policy Effects to view supporting evidence. Existing clause links also open here.